How bisphosphonates work, biochemical level Jukka Mönkkönen (Kuopio, Finland) and Mike Rogers (Sydney, Australia)
|
|
|
- Debra Chambers
- 5 years ago
- Views:
Transcription
1 Bisphosphonates2019 Celebrating 50 years July 2019 The Edge Sheffield Outline as at 20 December more speakers/faculty to be added Monday 15 July The Past Introduction and early history Graham Russell (Sheffield and Oxford, UK) Individual bisphosphonates: historical perspective Etidronate Nelson Watts (Cincinnati, USA) Alendronate Steve Cummings (San Francisco, USA) Risedronate Mike McClung (Portland, USA) Zoledronate Ian Reid (Auckland, New Zealand) Clodronate Eugene McCloskey (Sheffield, UK) Ibandronate Dieter Felsenberg (Berlin, Germany) The Leiden experience Socrates Papapoulos (Leiden, Netherlands) Mechanisms of action How bisphosphonates work, biochemical level Jukka Mönkkönen (Kuopio, Finland) and Mike Rogers (Sydney, Australia) How bisphosphonates work, tissue level tbc Pharmacological evaluation of bisphosphonates Serge Cremers (New York, USA) Action of bisphosphonates on cancer Philippe Clézardin (Lyon, France)
2 Imaging Radiolabelled bisphosphonates for clinical imaging and therapy Gary Cook (London, UK) Pyrophosphate updated The development of enzyme replacement for hypophosphatasia Philippe Crine (Montreal, Canada) Hypophosphatasia: historical perspective and current status Michael Whyte (St Louis, USA) Close
3 Tuesday 16 July The Present Current Issues with the Use of Bisphosphonates Osteoporosis Why are bisphosphonates not being used more to prevent fractures (the Treatment Gap ) Cyrus Cooper (Southampton and Oxford, UK) and Bente Langdahl (Aarhus, Denmark) Long-term effects of bisphosphonates on bone Dennis Black (San Francisco, USA) Practical guidance for use of bisphosphonates in osteoporosis Juliet Compston (Cambridge, UK) The challenge of long-term adherence, the role of bone turnover markers Richard Eastell (Sheffield, UK) Bone and Cancer Disease modifying effects of bisphosphonates in cancer Rob Coleman (Sheffield, UK) The use of bisphosphonates across solid tumours with established bone metastases Janet Brown (Sheffield, UK) Myeloma bone disease and bisphosphonates Matthew Drake (Rochester, USA) Snap posters Rare Bone Disease Osteogenesis imperfecta Nick Bishop (Sheffield, UK) Fibrous dysplasia Roland Chapurlat (Lyon, France) Orthopaedic Diseases Multiple applications in orthopaedics Mark Wilkinson (Sheffield, UK)
4 Paget s Disease Management of Paget s Disease Stuart Ralston (Edinburgh, UK) Litigation Matters Liability litigation: AFF, ONJ Ron Dhindsa (Washington DC, USA) Is the patent system fit for purpose? Sir Robin Jacob Close
5 Wednesday 17 July The Future Ageing and Lifespan Progeria and the biology of ageing tbc Effect of bisphosphonates on lifespan Jacqueline Center (Sydney, Australia) Musculoskeletal effects Mineralisation Osteoarthritis and bone marrow lesions Erik Fink Eriksen (Oslo, Norway) Bisphosphonates and pain Thomas Tzschentke (Aachen, Germany) Burn injury and restoration of muscle function Gordon Klein (Galveston, USA) Bone and muscle interactions in cancer Theresa Guise (Indianapolis, USA) Biological mineralisation mechanisms Marc McKee (Montreal, Canada) General arterial calcification of infancy, etidronate and ENPP1 replacement Demetrios Braddock (New Haven, USA) New Bisphosphonates, mechanisms, and applications Non classical actions - osteocytes, connexins, IG9402 Lilian Plotkin and Teresita Bellido (Indianapolis, USA) New bisphosphonates and use for drug delivery Hal Ebetino (Rochester, USA) Dental applications Parish Sedghizadeh (Los Angeles, USA) Delivery of chloroquine and anti-cancer agents to bone Brendan Boyce (Rochester, USA) Discussion and Close
St Catherine s College, Oxford. 30 June 3 July 2018
Saturday 30 June MolPharm 8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases/ Cancer and Bone Society 2018 Meeting St Catherine
Wednesday 27 June Talks in Stripe Auditorium Catering breaks, exhibition and poster viewing in Stripe Lecture Room, Stripe Studio 1 and 2
Bone Research Society Annual Meeting The University of Winchester, Winchester, UK 27-29 June 2018 Preliminary programme Wednesday 27 June 1200 Foyer, The Stripe Building Registration desk opens, coffee
6 th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases 28 June 2 July 2014
6 th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases 28 June 2 July 2014 St Catherine s College Oxford, UK Final Programme Advances
NAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
Final Programme. 5 th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease June 2012
5 th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease 27-30 June 2012 St Catherine s College Oxford, UK Final Programme 5 th International Workshop on Advances
Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
Recent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
St Catherine s College, Oxford. 30 June 3 July 2018
Saturday 30 June MolPharm 8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases/ Cancer and Bone Society 2018 Meeting St Catherine
Advanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
Imaging of the brain- a major investment into diseases of the brain
Imaging of the brain- a major investment into diseases of the brain Paul M. Matthews, MD, DPhil, FMedSci Edmond and Lily Safra Chair, Head, Division of Brain Sciences and Associate Director, UK Dementia
Advancing today s research; Fostering tomorrow s leaders
Advancing today s research; Fostering tomorrow s leaders Chair and meeting organiser: Roger Bouillon (Leuven, BE) Co-chairs: Christa Maes (Leuven, BE) Roland Baron (Boston, USA) Jack Martin (Melbourne,
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
Postmenopausal Osteoporosis
Osteoporosis Products Available in Canada for the Treatment and Prevention of Postmenopausal Osteoporosis Physician Desk Reference - 2nd Edition A clinical resource provided to you by: The Society of Obstetricians
An Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
For the Patient: Bisphosphonates and Oral Health in Multiple Myeloma
For the Patient: Bisphosphonates and Oral Health in Multiple Myeloma Regular dental care is very important for all cancer patients. As soon as possible after your cancer diagnosis, your dentist should
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
Talib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University
Talib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University 1 Biochemistry Interaction with Oral & Systemic Diseases Periodontal disease Jaw Bone Necrosis due to Bisphosphonate
Osteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
Edited by Annamária Kis with the cooperation of Dr. Gábor Papp, Prof. Ekkehart Tillmanns, Dr. Tamás G. Weiszburg
2 nd Report of the IMA Archive Edited by Annamária Kis with the cooperation of Dr. Gábor Papp, Prof. Ekkehart Tillmanns, Dr. Tamás G. Weiszburg 1 st Business Meeting 2 nd European Mineralogical Conference,
Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
Disclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
JUNE ANNEX SAROLGIO MANSION ATHENS WAR MUSEUM. IFCC-IFCC Working Group Standardization of Bone Markers
JUNE 10 2017 ATHENS WAR MUSEUM ANNEX SAROLGIO MANSION www.athens2017.org/go/satellite IFCC-IFCC Working Group Standardization of Bone Markers INTERNATIONAL SCIENTIFIC ORGANIZING COMMITTEE Chair University
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
The Use of Bisphosphonate Therapy for Osteoporosis in Childhood and Adolescence
The Use of Bisphosphonate Therapy for Osteoporosis in Childhood and Adolescence Position Paper Authors JA Batch, FRACP Dept. of Endocrinology and Diabetes, Royal Children's Hospital, Brisbane, Queensland.
FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment
These guidelines are endorsed by the following Lebanese Scientific Societies and Associations: Lebanese Society of Endocrinology Diabetes and Lipids, Lebanese Society of Rheumatology, Lebanese Society
Osteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
Bad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
Bisphosphonates in Oral Diseases: Updates of its implications in Dental Management
J. Int Oral Health 2012 Case Report All right reserved Bisphosphonates in Oral Diseases: Updates of its implications in Dental Management Jayalakshmi K * Ravikumar H Jaya Naidu Archana Patil *MDS, Professor,
Bisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
THE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 119 No 1246 ISSN 1175 8716 Osteonecrosis of the jaw and bisphosphonates putting the risk in perspective Mark Bolland, David Hay, Andrew Grey, Ian Reid, Tim Cundy Abstract
Download slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
The widespread introduction of bisphosphonates into. Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
CONCISE REVIEW FOR CLINICIANS ADVERSE EFFECTS OF BISPHOSPHONATES AND OSTEOPOROSIS MANAGEMENT Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management KURT A. KENNEL, MD, AND MATTHEW
From Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
THE FOCUS FACTOR MINDFULNESS AT WORK
THE FOCUS FACTOR MINDFULNESS AT WORK May 16, 2016 MOIRA GARVEY DIRECTOR & SENIOR CONSULTANT, POTENTIAL PROJECT NORTH AMERICA MOIRA.GARVEY@POTENTIALPROJECT.COM WHY THE SUDDEN POPULARITY? Mindfulness Time,
Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation Below is the form you need to fill out. NAME Health Hawke s Bay DATE NOVEMBER 2012 TITLE OF ACTIVITY OSTEOPOROSIS
MolPharm Workshop 2-5 July 2016, Oxford, UK Speakers
MolPharm Workshop 2-5 July 2016, Oxford, UK Speakers Bo Abrahamsen Bo Abrahamsen is a Consultant Endocrinologist at Holbæk Hospital and Professor in Clinical Database Studies at the University of Southern
Approved. PASS INFORMATION Title
Date: 10 September 2015 Page 1 of 246 PASS INFORMATION Title Survey of Oncology Practitioners Prescribing XGEVA in Europe to Evaluate Their Knowledge of XGEVA Summary of Product Characteristics Pertaining
FRAX Based Guidelines: Is a Universal Model Appropriate?
FRAX Based Guidelines: Is a Universal Model Appropriate? Marlene Chakhtoura, MD Research Fellow Calcium Metabolism & Osteoporosis Program WHO Collaborating Center for Metabolic Bone Disorders American
Bisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
Task Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
Current Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
Lay summary of adjuvant bisphosphonates financial modelling
Lay summary of adjuvant bisphosphonates financial modelling Developed by Breast Cancer Now in collaboration with Professor Rob Coleman Cost of treatment and of potential savings taken from business case
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
Name of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
Outline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
Osteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
Topic 7 supplement strategies to improve hip fracture prevention and care
This supplementary information for Topic 7 introduces the national strategy proposed by Osteoporosis New Zealand, and is one of the readings required for the professional development activity. Policymakers,
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
Bone Protection and Improved Survival
Bone Protection and Improved Survival Professor Rob Coleman Weston Park Hospital Sheffield Cancer Research Centre University of Sheffield UK Trans Atlantique en Oncologie Paris November 20 th 21 st November
Yearly Zoledronic Acid in Postmenopausal Osteoporosis
c o r r e s p onde nc e Yearly Zoledronic Acid in Postmenopausal Osteoporosis To the Editor: In their report on the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal
1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
To prevent bone loss and fractures in postmenopausal
Online Exclusive Postmenopausal osteoporosis: Another approach to management The effectiveness of oral bisphosphonates is compromised by poor compliance. IV bisphosphonates provide another option. Practice
the 1st London Colloquium Status Epilepticus P R O G R A M M E The Institute of Child Health, Guilford Street, London WC1N
the 1st London Colloquium on Status Epilepticus P R O G R A M M E Thursday 12 Saturday 14 April, 2007 and Post-Conference Workshop, Sunday 15 April, 2007 The Institute of Child Health, Guilford Street,
Which Bisphosphonate? It s the Compliance!: Decision Analysis
J Bone Metab 2016;23:79-83 http://dx.doi.org/10.11005/jbm.2016.23.2.79 pissn 2287-6375 eissn 2287-7029 Original Article Which Bisphosphonate? It s the Compliance!: Decision Analysis You Jin Lee 1, Chan
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
Current Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
Controversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
Abstract. Osteonecrosis of the jaw (ONJ)
ca Applied Research Cite this article as: J Can Dent Assoc 2010;76:aXXX 2011;77:b147 Preventive Strategies and Clinical Implications for Bisphosphonate-Related Osteonecrosis of the Jaw: A Review of 282
The next best thing to fruits and vegetables
The next best thing to fruits and vegetables Largest selling whole food based product in the world Most thoroughly researched brand name nutritional product in the world Supported by leading health professionals
Bisphosphonates: Mode of Action and Pharmacology
SUPPLEMENT ARTICLE Bisphosphonates: Mode of Action and Pharmacology R. Graham G. Russell, MD, PhD Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom
Immunoreceptors and Immunotherapy
Immunoreceptors and Immunotherapy June 10-15, 2018 Snowmass, Colorado Co-Organizers: E. Sally Ward Texas A&M University Health Science Center Texas, USA Stephen A. Beers University of Southampton Southampton,
NATIONAL COST OF OBESITY SEMINAR. Dr. Bill Releford, D.P.M. Founder, Black Barbershop Health Outreach Program
NATIONAL COST OF OBESITY SEMINAR Dr. Bill Releford, D.P.M. Founder, Black Barbershop Health Outreach Program 1 INTRODUCTION According to the Center of Disease Control and Prevention, the American society
Bisphosphonates for Injection* Effective Date: July 28, 2009
Subject: Bisphosphonates for Injection* Effective Date: July 28, 2009 Department(s): Utilization Management Policy: Objective: Procedure: The use of injectable bisphosphonates is reimbursable for Plans
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
FYI ONLY Generic Name. Generics available. zoledronic acid N/A
Criteria Document: Reference #: PC/A011 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
Scientific Program for the CABS Meeting at ECTS. Rome, Italy
Scientific Program for the CABS Meeting at ECTS Rome, Italy CLINICAL DAY May 14, 2016 I. Welcome (9:00 to 9:05am, Peyman Hadji, Daniele Santini) II. Understanding the problem (9:05 to 10:40am, Chairs:
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
The Use of Adjuvant Bisphosphonates in the Treatment of Early-Stage Breast Cancer
The Use of Adjuvant Bisphosphonates in the Treatment of Early-Stage Breast Cancer Aju Mathew, MD, MPhil, and Adam M. Brufsky, MD, PhD Aju Mathew, MD, MPhil, is the chief fellow in hematology and medical
Osteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection
Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection Table of Contents Policy: Commercial Policy History References Coding Information Information Pertaining to All Policies
Identifying red flags when reassessing screening programmes.
Identifying red flags when reassessing screening programmes. On behalf of the screening re-assessment collaborating group: Karsten Juhl Jørgensen Deputy Director, MD, DrMedSci The The screening re-assessment
Bisphosphonates are made up of two phosphonic acids. Long-Term Use of Bisphosphonates in Osteoporosis. Nelson B. Watts and Dima L.
SPECIAL FEATURE Review Long-Term Use of Bisphosphonates in Osteoporosis Nelson B. Watts and Dima L. Diab University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati Ohio 45219 Context: Bisphosphonates
NIH Public Access Author Manuscript Calcif Tissue Int. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Calcif Tissue Int. 2010 January ; 86(1): 67 71. doi:10.1007/s00223-009-9315-x. Morphological Assessment of Basic Multicellular Unit
Osteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
Trends in presentation of bone and soft tissue sarcomas over 25 years little evidence of earlier diagnosis
Trends in presentation of bone and soft tissue sarcomas over 25 years little evidence of earlier diagnosis Royal Orthopaedic Hospital, Birmingham Rob Grimer, Lee Jeys, Gemma Smith, Graham Johnson Are we
Osteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
Urgent Medical Device Correction
Urgent Medical Device Correction Contact TM Detach Infusion Sets: Needle May Fracture From the Connect/Disconnect Location August 10, 2015 Dear Valued Customer: Unomedical a/s, a ConvaTec Company has initiated
Scottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
AACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
World Rowing Sports Medicine and Science Conference 2018 Berlin, Germany November 21-23, Hall DÖBLIN I+II Einstein I+II Ehrlich I +II Foyer
PROGRAM Wednesday, November 21 st 2018 Congress Overview Hall DÖBLIN I+II Einstein I+II Ehrlich I +II Foyer 14:00 Welcome Session 15:00 Metabolic stress and nutrition Development 16:00 Break 17:00 Understand
Bone health in cancer patients: ESMO Clinical Practice Guidelines
clinical practice guidelines Annals of Oncology 25 (Supplement 3): iii124 iii137, 2014 doi:10.1093/annonc/mdu103 Published online 29 April 2014 clinical practice guidelines Bone health in cancer patients:
Use of Zoledronic Acid in the Treatment of Paget's Disease
Use of Zoledronic Acid in the Treatment of Paget's Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Seton, Margaret,
Emerging Data on the Role of Wnt Biology in Cancer
MEETING AGENDA Emerging Data on the Role of Wnt Biology in Cancer The Banbury Center, Cold Spring Harbor Laboratory, New York, USA October 7-10, 2018 This meeting was funded by Leap Therapeutics Lead Organizers:
Canadian Cochrane Network & Centre. Copyright 05/12/2009 by Phil Hahn
Systematic Reviews and The Cochrane Library Phil Hahn Queen s University Co-site Representative Canadian Cochrane Network & Centre Copyright 05/12/2009 by Phil Hahn Archie Cochrane It is surely a great
CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
AACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender
An overview of suicide statistics This document summarises information about suicide deaths in New Zealand covering up to 13. It does not attempt to explain causes of suicidal behaviour or causes of changes
Residual Cancer. May 3-5, International Symposium. on Minimal. Le Corum. > Preliminary. Program MONTPELLIER, FRANCE
International Symposium th on Minimal Residual Cancer > Preliminary Program May 3-5, 2018 Le Corum MONTPELLIER, FRANCE Organizers: www.ismrc2018.com > Committee & Speakers > Welcome to Montpellier Scientific
Upcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
FRAX-based assessment and intervention thresholds an exploration of thresholds in women aged 50 years and older in the UK
Osteoporos Int (1) 26:91 99 DOI.7/s198-1-3176- POSITION PAPER FRAX-based assessment and intervention thresholds an exploration of thresholds in women aged years and older in the UK E. McCloskey 1 & J.
DISCLOSURES SUNDEEP KHOSLA, M.D.
ADDRESSING PATIENT CONCERNS REGARDING COMPLICATIONS OF ANTIRESORPTIVE THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis Andreas Panagopoulos MD, PhD Upper Limb & Sports Medicine Orthopaedic Surgeon Assistant Professor, University of Patras Outline Teriparatide
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic